Tag: FDA safety alert
-
FDA Warns of Increased Risk of New Blood Cancers Linked to Tazverik
Tazverik, a prescription cancer drug used to treat certain rare cancers, has recently come under closer scrutiny by the U.S. Food and Drug Administration. In a safety alert, the FDA warned health care providers and patients about an increased risk of developing new blood cancers in people treated with Tazverik. This announcement has raised understandable